HC Wainwright Issues Positive Forecast for TRDA Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright increased their Q4 2024 earnings per share estimates for shares of Entrada Therapeutics in a report released on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.66) per share for the quarter, up from their previous forecast of ($0.67). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share.

Separately, Oppenheimer increased their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday.

Entrada Therapeutics Trading Up 3.1 %

Shares of Entrada Therapeutics stock opened at $19.82 on Friday. The firm has a market capitalization of $741.66 million, a PE ratio of 12.47 and a beta of -0.26. Entrada Therapeutics has a twelve month low of $10.75 and a twelve month high of $19.95. The firm’s 50-day moving average price is $16.40 and its 200 day moving average price is $15.68.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. The company had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.

Insider Transactions at Entrada Therapeutics

In other news, insider Natarajan Sethuraman sold 2,642 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the transaction, the insider now directly owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Nathan J. Dowden sold 1,904 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the completion of the sale, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at $1,898,759.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,187 shares of company stock valued at $155,947 over the last 90 days. 7.59% of the stock is currently owned by corporate insiders.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of Entrada Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after purchasing an additional 2,146 shares during the last quarter. US Bancorp DE purchased a new position in Entrada Therapeutics during the third quarter worth about $42,000. Acadian Asset Management LLC acquired a new stake in shares of Entrada Therapeutics during the first quarter valued at about $79,000. Rhumbline Advisers raised its stake in shares of Entrada Therapeutics by 25.3% in the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Entrada Therapeutics in the 3rd quarter worth approximately $156,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.